Solubility and crystal size of sirolimus in different organic solvents

Journal of Chemical and Engineering Data

Volumn 55, Issue 11, 2010, Pages 5050-5054

  Gandhi, Pankaj J ^a   Murthy, Z V P ^a  

^a SARDAR VALLABHBHAI NATIONAL INSTITUTE OF TECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOVASCULAR APPLICATIONS; CRYSTAL SIZE; GRAVIMETRIC METHODS; SIROLIMUS; TEMPERATURE RANGE;

ACETONE; CRYSTALS; DICHLOROMETHANE; ETHANOL; GRAIN SIZE AND SHAPE; METHANOL; SOLUBILITY;

ORGANIC SOLVENTS;

EID: 78449290197     PISSN: 00219568     EISSN: 15205134     Source Type: Journal    
DOI: 10.1021/je100626x     Document Type: Article

References (33)

1. Shin, M. S.; Kim, H. Preparation of poly (N-vinyl-2-pyrolidone) microparticles using supercritical anti solvent Clean Technol. 2008, 14, 242-247
2. Zhang, X.; Xia, Q.; Gu, N. Preparation of all-trans retinoic acid nanosuspensions Drug Dev. Ind. Pharm. 2006, 32, 857-863
3. Vezina, C.; Kudelski, A.; Sehgal, S. N. Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle J. Antibiot. (Tokyo) 1975, 28, 721-726
4. Sehgal, S. N. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression Clin. Biochem. 1998, 31, 335-340
5. Shen, L. J.; Wu, F. L. Nanomedicines in renal transplant rejection-focus on sirolimus Int. J. Nanomed. 2007, 2, 25-32
6. Simamora, P.; Alvarez, J. M.; Yalkowsky, S. H. Solubilization of rapamycin Int. J. Pharm. 2001, 213, 25-29
7. Speiser, P. P. Poorly soluble drugs: a challenge in drug delivery. In Emulsions and Nanosuspensions for the Formulation of Poorly Soluble Drugs Müller, R. H.; Benita, S.; Böhm, B. H. L., Eds.; Medpharm: Stuttgart, 1998; pp 15 - 28.
8. Merisko-Liversidge, E. Nanocrystals: resolving pharmaceutical formulation issues associated with poorly water-soluble compounds. Particles, Conference held in Orlando, Florida, USA, April 20 - 23, 2002, Paper # 45.
9. Junghanns, J. U.; Müller, R. H. Nanocrystal technology, drug delivery and clinical applications Int. J. Nanomed. 2008, 3, 295-310
10. Tong, W. Q. Practical aspects of solubility determination in pharmaceutical preformulation. Solvent Systems and Their Selection in Pharmaceutics and Biopharmaceutics; Springer: New York, 2007; Vol. 6, 137 - 149.
11. Park, J. S.; Park, Y. J.; Kang, H. W.; Kim, C. K. Solvent effects on physicochemical behavior of estradiols recrystallized for transdermal delivery Arch. Pharm. Res. 2008, 31, 111-116
12. Byrn, S. R.; Pfeiffer, R. R.; Stephenson, G.; Grant, D. J. W.; Gleason, W. B. Solid state pharmaceutical chemistry Chem. Mater. 1994, 6, 1148-1158
13. Brittain, H. G. Methods for characterization of polymorphs and solvates. In: Polymorphism in Pharmaceutical Solids; Brittain, H. G., Ed.; Marcel Dekker: New York, 1999; pp 227 - 278.
14. Vasquez, E. M. Sirolimus: a new agent for prevention of renal allograft rejection Am. J. Health Syst. Pharm. 2000, 57, 437-448
15. Virmani, R.; Guagliumi, G.; Farb, A.; Musumeci, G.; Grieco, N.; Motta, T.; Mihalcsik, L.; Tespili, M.; Valsecchi, O.; Kolodgie, F. D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious Circulation 2004, 109, 701-705
16. Jensen, L. O.; Maeng, M.; Thayssen, P.; Christiansen, E. H.; Hansen, K. N.; Galloe, A.; Kelbaek, H.; Lassen, J. F.; Thuesen, L. Neointimal hyperplasia after sirolimus-eluting and paclitaxel-eluting stent implantation in diabetic patients: the randomized riabetes and rrug-eluting stent (DiabeDES) intravascular ultrasound trial Eur. Heart J. 2008, 29, 2733-2741
17. Gradus-Pizlo, I.; Wilensky, R. L.; March, K. L.; Fineberg, N.; Michaels, M.; Sandusky, G. E.; Hathaway, D. R. Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: effects on restenosis and implications for catheter-based drug delivery J. Am. Coll. Cardiol. 1995, 26, 1549-1557
18. Dev, V.; Eigler, N.; Fishbein, M. C.; Tian, Y.; Hickey, A.; Rechavia, E.; Forrester, J. S.; Litvack, F. Sustained local drug delivery to the arterial wall via biodegradable microspheres Cathet. Cardiovasc. Diagn. 1997, 41, 324-332
19. Valéro, F.; Hamon, M.; Fournier, C.; Meurice, T.; Flautre, B.; Van Belle, E.; Lablanche, J. M.; Gosselin, B.; Bauters, C.; Bertrand, M. Intramural injection of biodegradable microspheres as a local drug- delivery system to inhibit neointimal thickening in a rabbit model of balloon angioplasty J. Cardiovasc. Pharmacol. 1997, 31, 513-519
20. Yang, X.; Wang, X. J.; Ching, C. B. Solubility of form r and form γ of glycine in aqueous solutions J. Chem. Eng. Data 2008, 53, 1133-1137
21. Gandhi, P. J.; Murthy, Z. V. P. Kinetic study of ultrasonic antisolvent crystallization of sirolimus Cryst. Res. Technol. 2010, 45, 321-327
22. Jing, D.; Wang, J.; Wang, Y. Solubility of penicilline sulfoxide in different solvents J. Chem. Eng. Data 2010, 55, 508-509
23. Liversidge, G. G.; Cundy, K. C. Particle size reduction for improvement of oral bioavailability of hydrophobic drugs. I. Absolute oral bioavailability of nanocrystalline danazole in beagle dogs Int. J. Pharm. 1995, 125, 91-97
24. Müller, R. H.; Jacobs, C.; Kayser, O. Nanosuspensions as particulate drug formulations in therapy- Rationale for development and what we can expect for the future Adv. Drug Delivery Rev. 2001, 47, 3-19
25. Zeta Potential of Colloids in Water and Waste Water. ASTM Standard D 4187-82; American Society for Testing and Materials, 1985.
26. Wang, L. T.; Yin, Q. X.; Zhang, M. J.; Wang, J. K. Solubility of acephate in different solvents from (292.90 to 327.60) K J. Chem. Eng. Data 2007, 52, 426-428
27. Apelblat, A.; Manzurola, E. Solubilities of o-acetylsalicylic, 4-aminosalic, 3,5,-dinitrosalicylic, and p-toluic acid and magnesim DLaspartate in water from T (278 to 348) K J. Chem. Thermodyn. 1999, 31, 85-91
28. Zhang, H. T.; Wang, J. K.; Chen, Y.; Nie, Q. Solubility of sodium cefotaxime in aqueous 2-propanol mixtures J. Chem. Eng. Data 2006, 51, 2239-2241
29. Mullin, J. W. Crystallization, 3rd ed.; Butterworth-Heinemann: Oxford, 2000.
30. Montgomery, D. C. Design and Analysis of Experiments, 5th ed.; John Wiley & Sons: New York, 2001.
31. Muller, R. H.; Keck, C. M. Challenges and solutions for the delivery of biotech drugs-a review of drug nanocrystal technology and lipid nanoparticles J. Biotechnol. 2004, 113, 151-170
32. Gassmann, P.; List, M.; Schweitzer, A.; Sucker, H. Hydrosols: alternatives for the parenteral application of poorly water soluble drugs Eur. J. Pharm. Biopharm. 1994, 40, 64-72
33. Radtke, M. Pure drug nanoparticles for the formulation of poorly soluble drugs New Drugs 2001, 3, 62-68